0
Skip to Content
CHOSA Oncology
Who We Are
About Us
Vision & Strategy
Mangement
Products
Platin-DRP™
LiPlaCis
Research
Investors
Financial Reports
Videos
Analysis
Share Information
Calendars
Corporate Governance
Corporate Social Responsibility
Rights Issue 2025
How to subscribe
News
Contact
Subscribe
English
Swedish
English
CHOSA Oncology
Who We Are
About Us
Vision & Strategy
Mangement
Products
Platin-DRP™
LiPlaCis
Research
Investors
Financial Reports
Videos
Analysis
Share Information
Calendars
Corporate Governance
Corporate Social Responsibility
Rights Issue 2025
How to subscribe
News
Contact
Subscribe
English
Swedish
English
Folder: Who We Are
Back
About Us
Vision & Strategy
Mangement
Folder: Products
Back
Platin-DRP™
LiPlaCis
Research
Folder: Investors
Back
Financial Reports
Videos
Analysis
Share Information
Calendars
Corporate Governance
Corporate Social Responsibility
Rights Issue 2025
How to subscribe
News
Contact
Subscribe
Folder: English
Back
Swedish
English

Scientific Articles

Nielsen, D. et al.

Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.

Journal of Clinical Oncology, May 31, 2023

Kappel Buhl, I. et al.

A Drug Response Predictor to Guide Treatment for Breast Cancer

Taylor and Francis, 2019

Kappel Buhl, I. et al.

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts

PloS One, 2018; 10.1371

Hugger Jacobsen, E et. al.

Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study

Journal of Clinical Oncology, 2018, e13077

Vangsted, A.J. et al.

Drug response prediction in high-risk multiple myelomas

National Library of Medicine, 2018

Kappel Buhl, I. et. al.

Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer

Abstract no.: e20007, ASCO Annual Meeting, Chicago, 2016

Lassen et. al.

Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumor

Cancer Research 76 (14 supplement), July 2016

CHOSA Oncology

Ole Maaløes Vej 3, 2200 København (Denmark)
c/o ECIT Services, AB Kungsgatan 6, 211 49 Malmö (Sweden)
 Org.no: 559037-2271

Contact us

info@chosa.bio
+45 21 60 89 22